



IFW

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM AUG 10 2006 (to be used for all correspondence after initial filing) Total Number of Pages in This Submission	Application Number	10/097,814 10-577814
	Filing Date	April 28, 2006
	First Named Inventor	J. Lieberman
	Art Unit	To be assigned
	Examiner Name	To be assigned
	Attorney Docket Number	033393-55222

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Certificate of Mailing, Statement of Limited Recognition, IDS Form PTO-SB08, Copies of Cited References 2-43 and Return Receipt Postcard
Remarks No fees are believed to be due. However, the Commissioner is hereby authorized to charge any fees that may be due or credit any overpayment to Deposit Account Number 19-2380.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Nixon Peabody LLP		
Signature			
Printed name	David S. Resnick/Leena H. Karttunen		
Date	August 7, 2006	Reg. No.	34,235/L0207

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	Rebecca J. Goodwin	Date	August 7 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Practitioner's Docket No.: 033393/55222

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


APPLICANT: J. Lieberman et al. EXAMINER: To be assigned

SERIAL NO.: ~~10/557,814~~ 10/577814 GROUP: To be assigned

FILED: April 28, 2006

FOR: METHODS FOR TREATING AND PREVENTING ISCHEMIA-
REPERFUSION INJURY USING RNA INTERFERING AGENTS

MAIL STOP Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING	
I hereby certify that this correspondence, on the date shown below, is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to MAIL STOP AMENDMENT, Commissioner of Patents, Box 1450, Alexandria, VA 22313-1450.	
Date:	August 7, 2006
	 Rebecca J. Goodwin

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO/SB/08, for consideration by the Examiner in connection with the examination of the above-identified patent application.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

- X (1) within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits; or
- (2) within three months of the mailing date of the PCT International Search Report; or

10-577814

Serial Number ~~10/557,814~~

Information Disclosure Statement filed August 7, 2006

- (3) after the period defined in (1) but before the mailing date of a **Final Rejection or Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely **\$180.00**, is included herein; or
- (4) after the mailing date of a **Final Rejection or Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached form(s) PTO/SB/08 be made of record in this application. Copies of these documents:

X are enclosed herewith

X Pursuant to 37 C.F.R. §1.98, a copy of issued U.S. patent listed on the attached form PTO/SB/08, is no longer required and therefore are not enclosed. This document can be found in the U.S. PTO issued patents database.

Early examination and allowance of the present application are respectfully solicited.


FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to Nixon Peabody LLP Deposit Account No. 19-2380. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,

Date:

August 7, 2006



David S. Resnick (Reg. No. 34,235)
Leena H. Karttunen (L0207)
Nixon Peabody LLP
100 Summer Street
Boston, MA 02110-2131
(617) 345-6057



Practitioner's Docket No.: 033393/55222

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: J. Lieberman et al.

EXAMINER: To be assigned

SERIAL NO.: ~~10/557,814~~ **10577814**

GROUP: To be assigned

FILED: April 28, 2006

FOR: METHODS FOR TREATING AND PREVENTING ISCHEMIA-
REPERFUSION INJURY USING RNA INTERFERING AGENTS

CERTIFICATE OF MAILING (37 C.F.R. § 1.8 or 1.6(d))

I hereby certify that this correspondence:

1. Certificate of Mailing (1 pg.);
2. Statement of Limited Recognition (1 pg.);
3. Transmittal Form (1 pg.);
4. Information Disclosure Statement (2 pp.);
5. IDS Form PTO-SB08(a) and 08(b) (4pg);
6. Copies of Cited References 2-43; and
7. Return Receipt Postcard.

is on the date shown below being:


MAILING

X deposited with the United States Postal Service
sufficient postage as first class mail in an
envelope addressed to
Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Date: August 7, 2006

FACSIMILE

transmitted by facsimile to the Patent with
and Trademark Office to 1-571-273-8300.


Signature

Rebecca J. Goodwin
(type or print name of person certifying)



**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATES PATENT AND TRADEMARK OFFICE**


LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)

Leena H. Karttunen is hereby given limited recognition under 37 CFR § 11.9(b) as an employee of Nixon Peabody LLP, to prepare and prosecute patent applications wherein the patent applicant is the client of Nixon Peabody LLP and an attorney or agent of record in the applications is a registered practitioner who is a member of Nixon Peabody LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Leena H. Karttunen ceases to lawfully reside in the United States, (ii) Leena H. Karttunen's employment with Nixon Peabody LLP ceases or is terminated, or (iii) Leena H. Karttunen ceases to remain or reside in the United States on an H-1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Limited Recognition No. L0207
Expires: February 11, 2007

Harry I. Moatz
Director of Enrollment and Discipline



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form PTO/SB/08A (10-01) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
Sheet		1	of	4	Attorney Docket Number	033393/55222
U.S. PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	U.S. Patent Document Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1	US-6,228,642 B1	05-08-2001	Baker et al.		
FOREIGN PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ⁵
	2	ASHKENAZI, A. and DIXIT, V.M. <i>Science</i> 281:1305-1308 (1998)				
	3	CHIU & RANA, <i>RNA</i> 9:1034-1048 (2003)				
	4	DEL ZOPPO, G.J., K.M.A. Welch, L.R. Caplan, D.J. Reis, et al., (Eds.) pp.217-220 Academic Press, San Diego (1997)				
	5	FLOYD & CARNEY, <i>Ann. Neurol.</i> 32:S22-S27 (1992).				
	6	GREEN, D.R. and EVAN, G.I. <i>Cancer Cell</i> 1:19-30 (2002)				
	7	HAMADA et al., <i>Antisense Nucleic Acid Drug Dev.</i> 12:301-309 (2002)				
	8	HERWEIJER & WOLFF, <i>Gene Therapy</i> 10:453-458 (2003)				
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
				Application Number		10/557,814 10/557,814 10/577,814	
				Filing Date		April 28, 2006	
				First Named Inventor		J. Lieberman et al.	
				Group Art Unit		To Be Assigned	
Examiner Name		To Be Assigned					
Sheet	2	of	4	Attorney Docket Number		033393/55222	
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²	
	9	HEYMAN et al., <i>Curr. Opin. Crit. Care</i> . 8(6):526-34. (2002)					
	10	JACKSON et al., <i>Nat. Biotechnol.</i> 21(6):635-637 (2003)					
	11	LIU, K.D., <i>Crit. Care Med.</i> 31(8)(Suppl.):S572-S581 (2003)					
	12	LEE et al., <i>Am. J. Physiol. Heart Circ. Physiol.</i> 284:H456-H463 (2003)					
	13	LEWIS et al., <i>Nature Genetics</i> 32:107-108 (2002)					
	14	MARUYAMA et al., <i>J. Gene. Med.</i> 4:333-341 (2002)					
	15	MARUYAMA et al., <i>Hum. Gene Ther.</i> 13:455-468 (2002)					
	16	MATTSON, M.P. <i>Nat. Rev. Mol. Cell. Biol.</i> 1:120-128 (2002)					
	17	MCCAFFREY et al., <i>Nature</i> 418:38-39 (2002)					
	18	MENÈ et al., <i>J. Nephrol.</i> 16:186-195 (2003)					
	19	MEIER, P., et al., <i>Nature</i> 407:796-801 (2000)					
	20	MOGI et al., <i>Lab. Invest.</i> 81(2):177-184 (2001)					
	21	NAGATA & SUDA, <i>Immunology Today</i> 16(1):39-43 (1995)					
Examiner Signature					Date Considered		

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
				Application Number		10/557,814- 10/577B/4	
				Filing Date		April 28, 2006	
				First Named Inventor		J. Lieberman et al.	
				Group Art Unit		To Be Assigned	
Examiner Name		To Be Assigned					
Sheet	3	of	4	Attorney Docket Number		033393/55222	
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²	
	22	NANSEN et al., <i>Blood</i> 99(4):1237-1245 (2002)					
	23	NOGAE et al., <i>J. Am. Soc. Nephrol.</i> 9(4):620-631 (1998)					
	24	ORTIZ et al., <i>Current Drug Targets - Immune, Endocrine & Metabolic Disorders</i> 2:181-192 (2002)					
	25	PASCHEN, W., <i>J. Cereb. Blood Flow Metab.</i> 23(7):773-779 (2003)					
	26	PRAKAS et al., <i>Ren. Fail.</i> 25(2):225-233 (2003)					
	27	RATHMELL, J.C. and THOMPSON, C.B. <i>Cell</i> 109 (Suppl.): S97-S107 (2002)					
	28	REITER et al., <i>Ann. N.Y. Acad. Sci.</i> 993:35-47 (2003)					
	29	ROWE, P.M., Glimmers of clinical relevance for Fas (1996) <i>Lancet</i> , 347: 1398					
	30	SATA & WALSH, <i>J. Biol. Chem.</i> 273(50):33103-33106 (1998)					
	31	SCAFFIDI et al., <i>J. Biol. Chem.</i> 274(3):1541-1548 (1999)					
	32	SLEDZ et al., <i>Nat. Cell Biol.</i> 5(9):834-839 (2003)					
	33	SONG et al., <i>Nat. Med.</i> 9(3):347-351 (2003)					
Examiner Signature					Date Considered		

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
10051336.2

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/557,814 10/577814
				Filing Date	April 28, 2006
				First Named Inventor	J. Lieberman et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	4	of	4	Attorney Docket Number	033393/55222
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	34	SØRENSEN, Dag R. et al., <i>J. Mol. Biol.</i> ; 327:761-766 (2003)			
	35	TEOH & FARRELL, <i>J. Gastroenterol. Hepatol.</i> 18:891-902 (2003)			
	36	THADHANI et al., <i>N. Engl. J. Med.</i> 334:1448-60 (1996)			
	37	VAUX, D.L. and KORSMEYER, S.J. <i>Cell</i> 96:245-254 (1999)			
	38	VERMUELEN, K., et al. <i>Cell Prolif.</i> 36:165-175 (2003)			
	39	WALL, Nathan R. et al., <i>The Lancet</i> ; 362:1401-1403 (2003)			
	40	WATANABE-FUKUNAGA, R., et al., <i>J. Immunol.</i> , 148:1274-1279 (1992)			
	41	ZHANG et al., <i>Hum. Gene Ther.</i> 10:1735-1737 (1999)			
	42	ZHANG et al., <i>J. Biol. Chem.</i> 277(40):37430-37438 (2002)			
	43	ZÖRNIG, M., et al., <i>Biochim. Biophys. Acta</i> 1551:F1-F37 (2001)			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.